OncoCyte (OCX) Reports Q3 Loss, Lags Revenue Estimates Posted byZacks Equity Research November 9, 2021 Leave a comment on OncoCyte (OCX) Reports Q3 Loss, Lags Revenue Estimates OncoCyte (OCX) delivered earnings and revenue surprises of -57.14% and -69.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?